Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + Dexamethasone in Chinese RRMM
NCT03029234Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2017
- Primary completion
- Nov 2018
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, open-label trial of carfilzomib in multiple myeloma (MM), sponsored by Amgen. Primary endpoint: Overall Response Rate up to 8.9 months. Started Mar 2017; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03029234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029234.